Health economic assessment of universal immunization of toddlers against Hepatitis A Virus (HAV) in Mexico
| Autor: | Luis Romano-Mazzotti, Jorge A. Gómez, Pablo Anaya, Fernando Carlos |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Adult
Male Pediatrics medicine.medical_specialty economic evaluation Adolescent Cost effectiveness Cost-Benefit Analysis Immunology 03 medical and health sciences Indirect costs Young Adult 0302 clinical medicine Environmental health Per capita Immunology and Allergy Medicine Humans 030212 general & internal medicine Child Mexico cost-effectiveness Aged Pharmacology Aged 80 and over Hepatitis A Vaccines 030505 public health business.industry Public health Vaccination Hepatitis A Infant Middle Aged medicine.disease Research Papers Immunization Child Preschool Economic evaluation Quality of Life Female 0305 other medical science business |
| Zdroj: | Human Vaccines & Immunotherapeutics |
| ISSN: | 2164-554X |
| Popis: | Hepatitis A virus (HAV) has shifted from high to intermediate endemicity in Mexico, which may increase the risk of clinically significant HAV infections in older children, adolescents and adults. The objective of this study was to evaluate the cost-utility of single-dose or 2-dose universal infant HAV vaccination strategy in Mexico, compared with no vaccination. A previously published dynamic model estimated the expected number of HAV cases with each strategy, and a decision model was used to estimate the costs and quality-adjusted life-years (QALYs) expected with each strategy. The time horizon was 25 years (2012-2036) and the base case analysis was conducted from the perspective of the Mexican public health system. Costs and QALYs after the first year were discounted at 5% annually. Input data were taken from national databases and published sources where available. The single-dose HAV vaccination strategy had an incremental cost-utility ratio (ICUR) of Mexican peso (MXN) 2,270 per QALY gained, compared with no vaccination. The two-dose strategy had an ICUR of MXN 14,961/QALY compared with no vaccination, and an ICUR of MXN 78,280/QALY compared with the single-dose strategy. The estimated ICURs were below the threshold of 1 x Mexican gross domestic product per capita. When indirect costs were included (societal perspective), the single-dose HAV vaccination strategy would be expected to improve health outcomes and to be cost-saving. This analysis indicates that routine vaccination of toddlers against HAV would be cost-effective in Mexico using either a single-dose or a 2-dose vaccination strategy. GSK study identifier: HO-12-12877. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|